Aurobindo Pharma Subsidiary Enters Distribution Agreement with STADA for Biosimilars in EU
Aurobindo Pharma Ltd announced on March 25, 2026, that CuraTeQ Biologics Private Limited, a wholly-owned subsidiary focused on biosimilars, has entered into a marketing and distribution agreement with STADA Arzneimittel AG.Under the agreement, STADA will market and distribute two biosimilars, already approved by the European Medicines Agency (EMA), developed by CuraTeQ in select European Union territories, including France and Germany. New brand names will be created and registered for each biosimilar. The agreement is anticipated to broaden CuraTeQ's market reach and drive revenue growth, utilizing STADA's established distribution network across EU markets.
Aurobindo Pharma Ltd. has classified this development as not being a material event.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.